An Explorative, Single Center, Open-labeled, Phase I Study to Evaluate the Feasibility and Safety of Intra-tumoral, Intra-peritoneal, and Subcutaneous Injections With IMP321 (LAG-3Ig Fusion Protein) for Advanced Stage Solid Tumor Entities

Trial Profile

An Explorative, Single Center, Open-labeled, Phase I Study to Evaluate the Feasibility and Safety of Intra-tumoral, Intra-peritoneal, and Subcutaneous Injections With IMP321 (LAG-3Ig Fusion Protein) for Advanced Stage Solid Tumor Entities

Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Sep 2017

At a glance

  • Drugs IMP 321 (Primary) ; IMP 321 (Primary) ; IMP 321 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Proof of concept
  • Acronyms INSIGHT
  • Most Recent Events

    • 13 Sep 2017 Status changed from not yet recruiting to recruiting.
    • 09 Sep 2017 Trial design presented at the 3rd CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
    • 09 Jul 2017 According to Prima BioMed media release, company has recieved regulatory (German Federal Ministry of Health) and ethical approvals for initiation of this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top